Understanding How Diabetes Affects Patient Response To Medications

Start Page: 14
Robert G. Smith DPM, MSc, RPh, CPed

1. Engelau MM, Geiss LS, Saaddine JB, et al. The evolving diabetes burden in the United States. Ann Intern Med. 2004;140(11):945-950.
2. Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. Int J Clin Pract. 2006;60(11):1471-1483.
3. Rendell M, Lassek WD, Ross DA, et al. A pharmaceutical profile of diabetic patients. J Chronic Dis. 1983;36(2):193-202.
4. Isacson D, Stallhammer J. Prescription drug use among diabetics: a population study. J Chronic Dis. 1987;40(7):651-660.
5. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet. 1991; 20(6):447-490.
6. Dostalek M, Akhlaghi F, Puzanovova M. Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin Pharmacokinet. 2012;51(8):481-499.
7. Ma J, Rayner CK, Jones KL, et al. Diabetic gastroparesis: diagnosis and management. Drugs. 2009;69(8):971-986.
8. Bonadonna RC, Groop L, Kraemer, et al. Obesity and insulin resistance in humans: a dose-response study. Metabolism.1990;39(5);452-459.
9. Worner W, Pressner A, Riebrock N. Drug-protein binding kinetics in patients with type 1 diabetes. Eur J Clin Pharmacol. 1992;43(1):97-100.
10. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination. In (Hardman JG, Limbird LE, eds.) Goodman and Gilman’s The Pharmacological Basis of Therapeutics, McGraw Hill, New York, 1996, pp. 3-27.
11. Hansten PD, Horn JR. Drug interaction mechanisms: enzyme induction. In: Hansten and Horn’s Drug Interactions Analysis and Management. Facts and Comparison, St. Louis, MO, 2003, pp. PM1-PM-15.
12. Bauer LA. Clinical Pharmacokinetics and pharmacodynamics. In (Dipro JT, ed.) Pharmacotherapy: A Pathophysiologic Approach, Appleton & Lange, Stamford, CT, 1999, pp. 21-30.
13. Kotlyar M, Carson SW. Effects of obesity on cytochrome P450 enzyme system. Int J Clin Pharmacol Ther. 1999;37(1):8-19.
14. Brill MJ, Diepstraten J, van Rongen A, et al. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmcokinet. 2012; 51 (5):277-304.
15. Dostalek M, Court MH, Yan B, et al. Significantly reduced cytochrome P 450 3A4 expression and activity in liver from humans with diabetes mellitus. Br J Pharmacol. 2011;163(5):937-947.
16. Raine AE. The rising tide of diabetic nephropathy: the warning before the flood? Nephrol Dial Transplant 1995; 10 (4):460-461.
17. Meeme A, Kasozi H. Effect of glycaemic control on glomerular filtration rate in diabetes mellitus patients. Afr Health Sci. 2009;9(Suppl. 1):S23-S26.
18. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65(8):757-73.

image description image description

Post new comment

  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

More information about formatting options

Enter the characters shown in the image.